Product Details
Are you ready for the unique opportunities and challenges coming to clinical trials in the next decade?
It’s a landmark time for clinical trials, with a whirlwind of recent changes that shows no signs of slowing down. From remote monitoring to virtual trials to lessons learned from COVID-19, those involved in conducting clinical trials must transform their operations.
Pamela Tenaerts, MD, MBA, executive director of the Clinical Trials Transformation Initiative (CTTI), a public-private partnership founded by Duke University and the FDA, and CTTI’s co-chair, John H. Alexander, MD, MHS, FACC, will discuss the future of clinical research — one that is patient-centered and easily accessible, integrated with health processes, leverages available data and improves public health — and the critical role of organizational partnerships to achieve quality results in the next generation of clinical trials.
Presentation Takeaways:
- Multi-stakeholder perspectives on the future of clinical research
- Future goals for clinical trials by 2030 using a Quality by Design approach
- Potential impacts of the COVID-19 pandemic to positively transform clinical trials
- How organizational collaborative efforts can help advance and enhance the clinical trials landscape
- Actionable tools and resources available from CTTI that can help organizations and researchers prepare and adapt for future change
If you conduct clinical trials, this presentation is a must.
About CTTI
CTTI now comprises more than 80 organizations from across the clinical trial enterprise. Members include representatives of government agencies, industry representatives, patient advocacy groups, professional societies, investigator groups, academic institutions, and other interested parties. CTTI’s mission is to develop and drive adoption of practices that will increase the quality and efficiency of clinical trials.
Meet Your Presenters
Pamela Tenaerts, MD, MBA is executive director at the Clinical Trials Transformation Initiative (CTTI) where she works closely with the Executive Committee to develop and implement strategies to accomplish the organization’s mission. She orchestrates efforts to effectively engage all interested stakeholders to improve the conduct of clinical trials. She is on the Board of Directors for the Society of Clinical Trials and a member of DIA’s Advisory Council North America and DiMe Society’s Scientific Advisory Board. Dr. Tenaerts is an independent director on the board of TRxADE Group, Inc. She practiced medicine in both the emergency department and in a private practice setting before embarking on a career in research. Dr. Tenaerts has obtained Six Sigma Green Belt certification.
John H. Alexander, MD, MHS, FACC is co-chair of CTTI. He is a cardiologist and professor of medicine in the Department of Medicine and Division of Cardiology at Duke University, as well as the vice chief for clinical research in the Division of Cardiology. Dr. Alexander is the director of cardiovascular research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and other clinical research programs. He has published extensively and has served on the steering committee and as the principal investigator of numerous multi-center clinical trials.
Who Will Benefit
- Clinical Research Professionals
- Medical Affairs Professionals
- Statistics/Biostatics Professionals
- R&D Personnel
- Marketing/Post-marketing Professionals
- Data Science Professionals